Aileron Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Rein Therapeutics, Inc. files an amendment to its 2025 10-K report, primarily to include previously omitted information regarding directors, executive officers, and corporate governance.
Rein Therapeutics, a clinical-stage biopharmaceutical company, reported significant net losses and raised substantial doubt about its ability to continue as a going concern, leading to an indefinite pause in LTI-01 and preclinical programs.
Rein Therapeutics files an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive compensation, and corporate governance.
Rein Therapeutics reports its 10-K filing, highlighting positive clinical data for LTI-03 but also raising concerns about its ability to continue as a going concern due to insufficient funds.
Aileron Therapeutics has filed an amendment to its annual report to include information previously omitted regarding directors, executive compensation, and corporate governance.
10-K: Aileron Therapeutics Shifts Focus to Pulmonary and Fibrosis, Completes Lung Therapeutics Acquisition
Aileron Therapeutics has completed its acquisition of Lung Therapeutics, shifting its focus to orphan pulmonary and fibrosis indications and advancing clinical programs for LTI-03 and LTI-01.